Clinical significance of eosinopenia in patients with coronavirus disease 2019_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

 CHENG Yusheng ¹ , ZHOU Yun ² , ZHU Mengde ³ , YANG Jianghua ⁴ , LU Zhiwei ¹

1. Department of Respiratory and Critical Care Medicine, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P. R. China;
2. Department of Respiratory and Critical Care Medicine, Second People’s Hospital of Wuhu, Wuhu, Anhui 241000, P. R. China;
3. Department of Respiratory and Critical Care Medicine, First People’s Hospital of Hefei, Hefei, Anhui 230061, P. R. China;
4. Department of Infectious Diseases, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P. R. China;

Corresponding?author：

CHENG Yusheng, Email: chengys1222@126.com

Keywords：

Coronavirus disease 2019; Eosinophil; Lymphocyte

DOI：

10.7507/1671-6205.202102050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To describe clinical significance of eosinopenia in patients with coronavirus disease 2019 (COVID-19).Methods This was a retrospective study conducted in three tertiary hospitals from Anhui province, China. A total of 59 patients with COVID-19 were consecutively reviewed from January 23, 2020 to March 10, 2020.Results The median age of patients with COVID-19 was 39 years old, and 32 were male, 30 with eosinopenia. Cough, sputum and fatigue were more common symptoms in eosinopenia patients compared with non-eosinopenia patients. The counts of blood lymphocytes (median: 101 cells/μL) in eosinopenia patients were significantly less than those of non-eosinopenia patients (median: 167 cells/μL, P<0.001). COVID-19 patients with eosinopenia had a higher proportion of corticosteroids therapy than patients with non-eosinopenia (50.0% vs. 13.8%, respectively, P=0.005). Decreased blood lymphocytes count was an independent risk factor for eosinopenia in COVID-19 patients (odds ratio 6.566, 95%CI 1.101 - 39.173, P=0.039).Conclusions Blood eosinopenia is frequent in COVID-19 patients. Patients with eosinopenia have different clinical features compared to patients with non-eosinopenia. Decreased lymphocyte count is an independent risk factor for eosinopenia in COVID-19 patients.

Citation： CHENG Yusheng, ZHOU Yun, ZHU Mengde, YANG Jianghua, LU Zhiwei. Clinical significance of eosinopenia in patients with coronavirus disease 2019. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(5): 315-319. doi: 10.7507/1671-6205.202102050 Copy

1.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
2.	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
3.	Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523.
4.	Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J, 2020, 55(6): 2000562.
5.	Pan A, Liu L, Wang C, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA, 2020, 323(19): 1-9.
6.	Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med, 2020, 201(11): 1380-1388.
7.	Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis, 2020, 71(15): 762-768.
8.	Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest, 2020, 130(5): 2620-2629.
9.	Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, 368: m1091.
10.	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
11.	Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379.
12.	Liu F, Xu AF, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis, 2020, 95: 183-191.
13.	Flores-Torres AS, Salinas-Carmona MC, Salinas E, et al. Eosinophils and respiratory viruses. Viral Immunol, 2019, 32(5): 198-207.
14.	Tiwary M, Rooney RJ, Liedmann S, et al. Eosinophil responses at the airway epithelial barrier during the early phase of influenza A virus infection in C57BL/6 mice. Cells, 2021, 10(3): 509.
15.	Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol, 2020, 153(6): 725-733.
16.	姚小紅, 李廷源, 何志承, 等. 新型冠狀病毒肺炎(COVID-19)三例遺體多部位穿刺組織病理學研究. 中華病理學雜志, 2020, 49(5): 411-417.
17.	Djangang NN, Peluso L, Talamonti, M, et al. Eosinopenia in COVID-19 patients: a retrospective analysis. Microorganisms, 2020, ; 8(12): 1929.
18.	Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol, 2020, 92(6): 577-583.
19.	Borges do Nascimento IJ, Cacic N, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med, 2020, 9(4): 941.
20.	楊碩, 蘇斌濤, 陳菁, 等. 糖皮質激素對新型冠狀病毒肺炎患者 T 淋巴細胞亞群的影響. 中國呼吸與危重監護雜志, 2021, 20(3): 159-163.
21.	Delshad M, Tavakolinia N, Sigaroodi AP, et al. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. Int Immunopharmacol, 2021, 95: 107586.
22.	徐佳麗, 胡蓓蓓, 茅秋霞, 等. 新型冠狀病毒肺炎患者的靜脈血栓栓塞癥風險評估與抗凝治療. 中國呼吸與危重監護雜志, 2021, 20(2): 101-105.
23.	Kassin MT, Varble N, Blain M, et al. Generalized chest CT and lab curves throughout the course of COVID-19. Sci Rep, 2021, 11(1): 6940.
24.	Ali A, Noman M, Guo Y, et al. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Sci Rep, 2021, 11(1): 5975.
25.	Canzano P, Brambilla M, Porro B, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci, 2021, 6(3): 202-218.
26.	Zuo ZH, Wu T, Pan LY, et al. Modalities and mechanisms of treatment for coronavirus disease 2019. Front Pharmacol, 2021, 11: 583914.
27.	Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med, 2020, 46(2): 315-328.
28.	Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol, 2021, 894: 173854.
29.	Sarma A, Christenson S, Mick E, et al. COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone[EB/OL]. Res Sq [Preprint]. [2021-01-14]. rs. 3. rs-141578. https://assets.researchsquare.com/files/rs-141578/v1_stamped.pdf.

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med, 2020, 382(8): 727-733.
3. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020, 395(10223): 514-523.
4. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J, 2020, 55(6): 2000562.
5. Pan A, Liu L, Wang C, et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA, 2020, 323(19): 1-9.
6. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med, 2020, 201(11): 1380-1388.
7. Qin C, Zhou LQ, Hu ZW, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis, 2020, 71(15): 762-768.
8. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest, 2020, 130(5): 2620-2629.
9. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ, 2020, 368: m1091.
10. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020, 382(18): 1708-1720.
11. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379.
12. Liu F, Xu AF, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis, 2020, 95: 183-191.
13. Flores-Torres AS, Salinas-Carmona MC, Salinas E, et al. Eosinophils and respiratory viruses. Viral Immunol, 2019, 32(5): 198-207.
14. Tiwary M, Rooney RJ, Liedmann S, et al. Eosinophil responses at the airway epithelial barrier during the early phase of influenza A virus infection in C57BL/6 mice. Cells, 2021, 10(3): 509.
15. Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol, 2020, 153(6): 725-733.
16. 姚小紅, 李廷源, 何志承, 等. 新型冠狀病毒肺炎(COVID-19)三例遺體多部位穿刺組織病理學研究. 中華病理學雜志, 2020, 49(5): 411-417.
17. Djangang NN, Peluso L, Talamonti, M, et al. Eosinopenia in COVID-19 patients: a retrospective analysis. Microorganisms, 2020, ; 8(12): 1929.
18. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol, 2020, 92(6): 577-583.
19. Borges do Nascimento IJ, Cacic N, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med, 2020, 9(4): 941.
20. 楊碩, 蘇斌濤, 陳菁, 等. 糖皮質激素對新型冠狀病毒肺炎患者 T 淋巴細胞亞群的影響. 中國呼吸與危重監護雜志, 2021, 20(3): 159-163.
21. Delshad M, Tavakolinia N, Sigaroodi AP, et al. The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19. Int Immunopharmacol, 2021, 95: 107586.
22. 徐佳麗, 胡蓓蓓, 茅秋霞, 等. 新型冠狀病毒肺炎患者的靜脈血栓栓塞癥風險評估與抗凝治療. 中國呼吸與危重監護雜志, 2021, 20(2): 101-105.
23. Kassin MT, Varble N, Blain M, et al. Generalized chest CT and lab curves throughout the course of COVID-19. Sci Rep, 2021, 11(1): 6940.
24. Ali A, Noman M, Guo Y, et al. Myoglobin and C-reactive protein are efficient and reliable early predictors of COVID-19 associated mortality. Sci Rep, 2021, 11(1): 5975.
25. Canzano P, Brambilla M, Porro B, et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci, 2021, 6(3): 202-218.
26. Zuo ZH, Wu T, Pan LY, et al. Modalities and mechanisms of treatment for coronavirus disease 2019. Front Pharmacol, 2021, 11: 583914.
27. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med, 2020, 46(2): 315-328.
28. Noreen S, Maqbool I, Madni A. Dexamethasone: therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol, 2021, 894: 173854.
29. Sarma A, Christenson S, Mick E, et al. COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone[EB/OL]. Res Sq [Preprint]. [2021-01-14]. rs. 3. rs-141578. https://assets.researchsquare.com/files/rs-141578/v1_stamped.pdf.

Chinese Journal of Respiratory and Critical Care Medicine

Clinical significance of eosinopenia in patients with coronavirus disease 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content